Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes

References

• Zinman B , Wanner C , Lachin JM , et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med . 373;2015:2117–2128. doi:10.1056/NEJMoa1504720 26378978
   PubMed Web of Science ®Google Scholar
• Neal B , Perkovic V , Mahaffey KW , et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med . 377;2017:644–657. doi:10.1056/NEJMoa1611925 28605608
   PubMed Web of Science ®Google Scholar
• Wanner C , Inzucchi SE , Lachin JM , et al; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med . 375;2016:323–334. doi:10.1056/NEJMoa1515920 27299675
   PubMed Web of Science ®Google Scholar
• Wiviott SD , Raz I , Bonaca MP , et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2diabetes. N Engl J Med . 380;2019:347–357. doi:10.1056/NEJMoa1812389 30415602
   PubMed Web of Science ®Google Scholar
• Perkovic V , Jardine MJ , Neal B , et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med . 380;2019:2295–2306. doi:10.1056/NEJMoa1811744 30990260
   PubMed Web of Science ®Google Scholar
• Zelniker TA , Wiviott SD , Raz I , et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet . 2019;393:31–39. doi:10.1016/S0140-6736(18)32590-X 30424892
   PubMed Web of Science ®Google Scholar
• Kaku K , Lee J , Mattheus M , Kaspers S , George J , Woerle HJ ; EMPA-REG OUTCOME® Investigators. Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease- results from EMPA-REG OUTCOME®. Circ J . 2017;81:227–234. doi:10.1253/circj.CJ-16-1148 28025462
   PubMed Web of Science ®Google Scholar
• Kadowaki T , Nangaku M , Hantel S , et al. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME® trial. J Diabetes Investig . 2019;10:760–770. doi:10.1111/jdi.12971
   PubMed Web of Science ®Google Scholar
• Ito H , Shinozaki M , Nishio S , Abe M . SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan. Expert Opin Pharmacother . 2016;17:2073–2084. doi:10.1080/14656566.2016.1232395 27592508
   PubMed Web of Science ®Google Scholar
• Nishio S , Abe M , Ito H . Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes Metab Syndr Obes . 2015;8:163–171. doi:10.2147/DMSO.S54679 25834461
   PubMed Web of Science ®Google Scholar
• Abe M , Ito H , Omoto T , et al. A case of diabetes mellitus complicated by cerebral infarction nine days after the initiation of a SGLT2 inhibitor. J Jpn Diabetes Soc . 2014;57:843~847 Japanese, abstract in English. doi:10.11213/tonyobyo.57.843
   Google Scholar
• Ministry of Health, Labor and Welfare. The National Health and Nutrition Survey in Japan; 2017 Available from: https://www.mhlw.go.jp/content/000451755.pdf. Accessed 7 2, 2019 Japanese.
   Google Scholar
• Ito H , Omoto T , Abe M , et al. Relationships between the duration of illness and the current status of diabetes in elderly patients with type 2 diabetes mellitus. Geriatr Gerontol Int . 2017;17:24–30. doi:10.1111/ggi.12654 26634299
   PubMed Web of Science ®Google Scholar
• Ito H , Oshikiri K , Mifune M , et al. The usefulness of the revised classification for chronic kidney disease by the KDIGO for determining the frequency of diabetic micro- and macroangiopathies in Japanese patients with type 2 diabetes mellitus. J Diabetes Complications . 2012;26:286–290. doi:10.1016/j.jdiacomp.2012.04.011 22621778
   PubMed Web of Science ®Google Scholar
• Ito H , Antoku S , Furusho M , et al. The prevalence of the risk factors for atherosclerosis among type 2 diabetic patients is greater in the progressive stages of chronic kidney disease. Nephron Extra . 2013;3:66–72. doi:10.1159/000353592 23904855
   PubMedGoogle Scholar
• Ito H , Mifune M , Abe M , et al. Hypertension resistant to antihypertensive agents commonly occurs with the progression of diabetic nephropathy in Japanese patients with type 2 diabetes mellitus: a prospective observational study. BMC Nephrol . 2012;13:48. doi:10.1186/1471-2369-13-48 22738384
   PubMed Web of Science ®Google Scholar
• Ito H , Abe M , Antoku S , et al. Comparison of the antidiabetic effects of linagliptin among groups with a normal renal function and a mild or severe renal impairment – retrospective observation study of Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother . 2015;16:289–296. doi:10.1517/14656566.2015.995091 25529857
   PubMed Web of Science ®Google Scholar
• Ito H , Ando S , Tsugami E , et al. Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes. Diabetes Res Clin Pract . 2019;153:41–48. doi:10.1016/j.diabres.2019.05.025 31150724
   PubMed Web of Science ®Google Scholar
• Green JB , Bethel MA , Armstrong PW , et al; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med . 373;2015:232–242. doi:10.1056/NEJMoa1501352 26052984
   PubMed Web of Science ®Google Scholar
• White WB , Cannon CP , Heller SR , et al; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med . 369;2013:1327–1335. doi:10.1056/NEJMoa1305889 23992602
   PubMed Web of Science ®Google Scholar
• Scirica BM , Bhatt DL , Braunwald E , et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med . 369;2013:1317–1326. doi:10.1056/NEJMoa1307684 23992601
   PubMed Web of Science ®Google Scholar
• Rosenstock J , Perkovic V , Johansen OE , et al; CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA . 321;2019:69–79. doi:10.1001/jama.2018.18269 30418475
   PubMed Web of Science ®Google Scholar
• Kim YG , Hahn S , Oh TJ , Kwak SH , Park KS , Cho YM . Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia . 2013;56(2013):696–708. doi:10.1007/s00125-012-2827-3 23344728
   PubMed Web of Science ®Google Scholar
• Terauchi Y , Yokote K , Nakamura I , Sugamori H . Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): interim results of a post-marketing surveillance study. Expert Opin Pharmacother . 2016;17:463–471. doi:10.1517/14656566.2016.1145668 26800061
   PubMed Web of Science ®Google Scholar
• Yokote K , Terauchi Y , Nakamura I , Sugamori H . Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study. Expert Opin Pharmacother . 2016;17:1995–2003. doi:10.1080/14656566.2016.1219341 27477242
   PubMed Web of Science ®Google Scholar
• Matsuo S , Imai E , Horio M , et al; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis . 53;2009:982–992. doi:10.1053/j.ajkd.2008.12.034 19339088
   PubMed Web of Science ®Google Scholar
• Zaman Z , Roggeman S , Cappelletti P , Ferrai G , Buxeda M , Barba N . Evaluation of aution max AX-4280 automated urine test-strip analyser. Clin Chem Lab Med . 2001;39:649–657. doi:10.1515/CCLM.2001.106 11522115
   PubMed Web of Science ®Google Scholar
• Ito H , Antoku S , Abe M , et al. An increase in the dose of telmisartan is effective in diabetic patients with poorly-controlled hypertension and proteinuria. Exp Clin Cardiol . 2014;20:3817–3823.
   Google Scholar
• Ito H , Antoku S , Mori T , et al. Association between chronic kidney disease and the cognitive function in subjects without overt dementia. Clin Nephrol . 2018;89:330–335. doi:10.5414/CN109188 29057735
   PubMed Web of Science ®Google Scholar
• Examination Committee of Criteria for ‘Obesity Disease’ in Japan; Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J . 2002;66:987–992. doi:10.1253/circj.66.987 12419927
   PubMed Web of Science ®Google Scholar
• Shimamoto K , Ando K , Fujita T , et al; Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension GUIDELINES for the management of hypertension (JSH 2014). Hypertens Res . 37;2014:253–390. doi:10.1038/hr.2014.20 24705419
   PubMed Web of Science ®Google Scholar
• Kario K , Okada K , Kato M , et al. Twenty-four-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation . 2019;139:2089–2097. doi:10.1161/CIRCULATIONAHA.118.037076
   Web of Science ®Google Scholar
• Sinclair A , Bode B , Harris S , et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord . 2014;14:37. doi:10.1186/1472-6823-14-37 24742013
   PubMed Web of Science ®Google Scholar
• Bode B , Stenlöf K , Sullivan D , Fung A , Usiskin K . Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995) . 2013;41:72–84. doi:10.3810/hp.2013.04.1020 23680739
   PubMedGoogle Scholar
• Perkovic V , Jardine M , Vijapurkar U , Meininger G . Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin . 2015;31:2219–2231. doi:10.1185/03007995.2015.1092128 26494163
   PubMed Web of Science ®Google Scholar
• Santer R , Calado J . Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol . 2010;5:133–141. doi:10.2215/CJN.04010609 19965550
   PubMed Web of Science ®Google Scholar
• Fitchett D , Zinman B , Wanner C , et al; EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J . 37;2016:1526–1534. doi:10.1093/eurheartj/ehv728 26819227
   PubMed Web of Science ®Google Scholar
• Kimura G . Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure. Circ J . 2016;80:2277–2281. doi:10.1253/circj.CJ-16-0780 27599528
   PubMed Web of Science ®Google Scholar
• Sasaki T , Sugawara M , Fukuda M . Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (luseogliflozin: the components of weight loss in Japanese patients with type 2 diabetes mellitus) study. J Diabetes Investig . 2019;10:108–117. doi:10.1111/jdi.12851
   PubMed Web of Science ®Google Scholar
• Sugiyama S , Jinnouchi H , Kurinami N , et al. Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes. J Atheroscler Thromb . 2018;25:467–476. doi:10.5551/jat.40873 29225209
   PubMed Web of Science ®Google Scholar
• Azoulay L , Suissa S . Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care . 2017;40:706–714. doi:10.2337/dc16-1943 28428321
   PubMed Web of Science ®Google Scholar
• Perna S , Mainardi M , Astrone P , et al. 12-month effects of incretins versus SGLT2-inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with type-2 diabetes mellitus. Clin Pharmacol . 2018;10:141–151. doi:10.2147/CPAA.S164785 30349407
   PubMed Web of Science ®Google Scholar
• Kambara T , Shibata R , Osanai H , et al. Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus. Geriatr Gerontol Int . 2018;18:108–114. doi:10.1111/ggi.13149 28861952
   PubMed Web of Science ®Google Scholar
• Claggett B , Lachin JM , Hantel S , et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease. Circulation . 2018;138:1599–1601. doi:10.1161/CIRCULATIONAHA.118.033810 30354516
   PubMed Web of Science ®Google Scholar